Ignite Creation Date:
2024-05-06 @ 5:50 PM
Last Modification Date:
2024-10-26 @ 2:36 PM
Study NCT ID:
NCT05444712
Status:
RECRUITING
Last Update Posted:
2023-09-28
First Post:
2022-06-08
Brief Title:
Transplantation After Complete Response In Patients With T-cell Lymphoma
Sponsor:
Hospices Civils de Lyon
Organization:
Hospices Civils de Lyon
Study Overview
Official Title:
Transplantation After Complete Response In Patients With T-cell Lymphoma
Status:
RECRUITING
Status Verified Date:
2023-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
TRANSCRIPT
Brief Summary:
Peripheral T-cell lymphoma PTCL encompasses a broad range of post-thymic ie mature sub-entities as defined by the 2017 WHO classification The most common entities are angioimmunoblastic T-cell lymphoma AITL and other Tfh-phenotype PTCL or PTCL not otherwise specified NOS each representing approximately 20 to 25 of mature T- and NKT-cell lymphomas Compared to their B-cell counterparts most PTCL confer dismal prognosis In fact except for anaplastic lymphoma kinase ALK-positive systemic anaplastic large cell lymphoma sALCL 10-year overall survival for patients with PTCL barely exceeds 30 Given the infrequency and the heterogeneity of these malignancies no real consensus on first-line treatment has been established for most PTCL
The place of autologous stem cell transplantation ASCT as a consolidation procedure for patients with PTCL achieving a complete metabolic response after induction is still highly debated ESMO recommendations and recent guidelines from a committee of the American Society for Blood and Marrow Transplantation currently propose ASCT as first-line therapy for transplant-eligible patients for all patients reaching at least a partial response PR after induction NCCN guidelines version 22017 recommend ASCT or observation in case of metabolic CR but salvage regimen in case of residual disease after induction
The place of autologous stem cell transplantation ASCT as a consolidation procedure for patients with PTCL achieving a complete metabolic response after induction is still highly debated ESMO recommendations and recent guidelines from a committee of the American Society for Blood and Marrow Transplantation currently propose ASCT as first-line therapy for transplant-eligible patients for all patients reaching at least a partial response PR after induction NCCN guidelines version 22017 recommend ASCT or observation in case of metabolic CR but salvage regimen in case of residual disease after induction
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None